Skip to main content
Top
Published in: Neurology and Therapy 1/2012

Open Access 01-12-2012 | Original Research

Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease

Authors: Joseph M. Ferrara, Giovanni Mostile, Christine Hunter, Octavian R. Adam, Joseph Jankovic

Published in: Neurology and Therapy | Issue 1/2012

Login to get access

Abstract

Introduction

Tetrabenazine (TBZ) reduces chorea related to Huntington disease (HD); however, it is uncertain whether this effect improves functionally relevant motor skills such as hand coordination and balance. The objective of this study was to provide pilot data regarding three motor function tests, which might be useful in monitoring symptom progression and therapeutic response, pending formal validation.

Methods

The authors assessed 11 ambulatory patients with HD-related chorea on two occasions: (1) while off TBZ (either prior to starting therapy or following a >24 h washout) and (2) when on a stable dose of TBZ, titrated to optimal effect. Study evaluations included the Jebsen-Taylor Hand Function Test (JTHFT) and Berg Balance Scale, a timed 25-foot walk, the Montreal Cognitive Assessment (MoCA) and the complete United Huntington Disease Rating Scale (UHDRS).

Results

Maximal chorea scores (UHDRS item 12) improved from 11.1 ± 2.9 to 8.5 ± 3.9 while on TBZ (P = 0.03), but we could not detect an improvement in functional measures while on TBZ in this small cohort. Scores of the JTHFT were globally slower than published normative data and correlated with MoCA summary scores, but not UHDRS chorea scores.

Conclusions

This pilot study did not detect significant functional gains with chorea suppression. The fact that performance on tests of hand function correlates with MoCA but not UHDRS chorea scores highlights the need for additional treatments targeted toward the cognitive aspects of HD.
Literature
1.
go back to reference Fenney A, Jog MS, Duval C. Bradykinesia is not a “systematic” feature of adult-onset Huntington’s disease; implications for basal ganglia pathophysiology. Brain Res. 2008;1193:67–75.PubMedCrossRef Fenney A, Jog MS, Duval C. Bradykinesia is not a “systematic” feature of adult-onset Huntington’s disease; implications for basal ganglia pathophysiology. Brain Res. 2008;1193:67–75.PubMedCrossRef
2.
go back to reference Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington’s disease: a 3-year follow-up study. Neurology. 2001;57:920–4.PubMedCrossRef Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington’s disease: a 3-year follow-up study. Neurology. 2001;57:920–4.PubMedCrossRef
3.
go back to reference Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef
4.
go back to reference Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11:136–42.CrossRef Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11:136–42.CrossRef
5.
go back to reference Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9:62.PubMedCrossRef Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9:62.PubMedCrossRef
6.
go back to reference Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969;50:311–9.PubMed Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969;50:311–9.PubMed
7.
go back to reference Berg KO, Maki BE, Williams JI, Holliday PJ, Wood-Dauphinee SL. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil. 1992;73:1073–80.PubMed Berg KO, Maki BE, Williams JI, Holliday PJ, Wood-Dauphinee SL. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil. 1992;73:1073–80.PubMed
8.
go back to reference Lynch DR, Farmer JM, Wilson RL, Balcer LJ. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord. 2005;20:777–82.PubMedCrossRef Lynch DR, Farmer JM, Wilson RL, Balcer LJ. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord. 2005;20:777–82.PubMedCrossRef
9.
go back to reference Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington’s disease. Mov Disord. 2010;25:401–4.PubMedCrossRef Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington’s disease. Mov Disord. 2010;25:401–4.PubMedCrossRef
10.
go back to reference Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6:7–17.PubMedCrossRef Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6:7–17.PubMedCrossRef
11.
go back to reference Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol. 2002;25:300–2.PubMedCrossRef Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol. 2002;25:300–2.PubMedCrossRef
12.
go back to reference Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord. 2007;22:10–3.PubMedCrossRef Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord. 2007;22:10–3.PubMedCrossRef
13.
go back to reference Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.PubMedCrossRef Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.PubMedCrossRef
14.
go back to reference Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31:127–33.PubMedCrossRef Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31:127–33.PubMedCrossRef
15.
16.
go back to reference Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington’s disease: which factors matter most? Mov Disord. 2009;24:574–8.PubMedCrossRef Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington’s disease: which factors matter most? Mov Disord. 2009;24:574–8.PubMedCrossRef
17.
go back to reference Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology. 2000;54:452–8.PubMedCrossRef Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology. 2000;54:452–8.PubMedCrossRef
18.
go back to reference Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington’s disease. Mov Disord. 1995;10:211–4.PubMedCrossRef Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington’s disease. Mov Disord. 1995;10:211–4.PubMedCrossRef
19.
go back to reference Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2003;74:120–2.PubMedCrossRef Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2003;74:120–2.PubMedCrossRef
20.
go back to reference Delval A, Krystkowiak P, Delliaux M, et al. Role of attentional resources on gait performance in Huntington’s disease. Mov Disord. 2008;23:684–9.PubMedCrossRef Delval A, Krystkowiak P, Delliaux M, et al. Role of attentional resources on gait performance in Huntington’s disease. Mov Disord. 2008;23:684–9.PubMedCrossRef
21.
go back to reference Rodrigues GR, Souza CP, Cetlin RS, et al. Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington’s disease. J Neurol. 2009;256:1809–15.PubMedCrossRef Rodrigues GR, Souza CP, Cetlin RS, et al. Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington’s disease. J Neurol. 2009;256:1809–15.PubMedCrossRef
22.
go back to reference Thompson JC, Poliakoff E, Sollom AC, Howard E, Craufurd D, Snowden JS. Automaticity and attention in Huntington’s disease: when two hands are not better than one. Neuropsychologia. 2010;48:171–8.PubMedCrossRef Thompson JC, Poliakoff E, Sollom AC, Howard E, Craufurd D, Snowden JS. Automaticity and attention in Huntington’s disease: when two hands are not better than one. Neuropsychologia. 2010;48:171–8.PubMedCrossRef
23.
go back to reference Cubo E, González M, Del Puerto I, FernándezArconada O, Garcia de Yebenes J. Impact of placebo treatment in Huntington’s disease: P05.025. Neurology. 2010;74(Suppl. 2):A413. Cubo E, González M, Del Puerto I, FernándezArconada O, Garcia de Yebenes J. Impact of placebo treatment in Huntington’s disease: P05.025. Neurology. 2010;74(Suppl. 2):A413.
24.
go back to reference Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1–9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959;127:103–9.PubMed Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1–9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959;127:103–9.PubMed
Metadata
Title
Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease
Authors
Joseph M. Ferrara
Giovanni Mostile
Christine Hunter
Octavian R. Adam
Joseph Jankovic
Publication date
01-12-2012
Publisher
Springer Healthcare Communications
Published in
Neurology and Therapy / Issue 1/2012
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-012-0005-7

Other articles of this Issue 1/2012

Neurology and Therapy 1/2012 Go to the issue